| Literature DB >> 33909068 |
Melisa M Shah1,2, Phillip P Salvatore1,2, Laura Ford1,2, Emiko Kamitani1, Melissa J Whaley1, Mitchell Kaitlin1,3, Dustin W Currie1,2, Clint N Morgan1, Hannah E Segaloff1,2,4, Shirley Lecher1, Tarah Somers1, Miriam E Van Dyke1,2, John Paul Bigouette1,2, Augustina Delaney1, Juliana DaSilva1, Michelle O'Hegarty1, Lauren Boyle-Estheimer1, Fatima Abdirizak1, Sandor E Karpathy1, Jennifer Meece5, Lynn Ivanic5, Kimberly Goffard6, Doug Gieryn6, Alana Sterkel7, Allen Bateman7, Juliana Kahrs8, Kimberly Langolf8, Tara Zochert8, Nancy W Knight1, Christopher H Hsu1, Hannah L Kirking1, Jacqueline E Tate1.
Abstract
Repeating the BinaxNOW antigen test for SARS-CoV-2 by two groups of readers within 30 minutes resulted in high concordance (98.9%) in 2,110 encounters. BinaxNOW test sensitivity was 77.2% (258/334) compared to real-time reverse transcription-polymerase chain reaction. Same day antigen testing did not significantly improve test sensitivity while specificity remained high. Published by Oxford University Press for the Infectious Diseases Society of America 2021. This work is written by (a) US Government employee(s) and is in the public domain in the US.Entities:
Keywords: BinaxNOW; COVID-19; SARS-CoV-2; antigen testing; diagnostic performance
Year: 2021 PMID: 33909068 PMCID: PMC8135465 DOI: 10.1093/cid/ciab309
Source DB: PubMed Journal: Clin Infect Dis ISSN: 1058-4838 Impact factor: 9.079